{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:01:36Z","timestamp":1784988096423,"version":"3.55.0"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180888, U10CA180819, U10CA180821, UG1CA233320"],"award-info":[{"award-number":["U10CA180888, U10CA180819, U10CA180821, UG1CA233320"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Anti-programmed death-1 (PD-1)\/cytotoxic T lymphocyte antigen-4 antibodies are efficacious in various malignancies. The potential role of dual checkpoint inhibitors in many rare solid tumors is not established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study presents the results of ipilimumab\u2013nivolumab in salivary gland neoplasm cohorts of the SWOG S1609 dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>DART is a prospective, open-label, multicenter (1016 US sites), multi-cohort phase II trial of ipilimumab (1\u2009mg\/kg intravenously (IV) every 6\u2009weeks) plus nivolumab (240\u2009mg IV every 2\u2009weeks).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We performed a prospective, multicenter phase II clinical trial of ipilimumab (1\u2009mg\/kg IV every 6\u2009weeks) plus nivolumab (240\u2009mg IV every 2\u2009weeks) in three salivary gland neoplasm cohorts: major and minor salivary gland and adenoid cystic cancers. Patients with adenoid cystic salivary gland tumors (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u200926) and other salivary gland neoplasms (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u200934) were evaluable. The most common site of origin was the parotid (31%,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u20098 adenoid cystic group; 68%,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u200923 remaining histologies).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In the adenoid cystic group, objective response rate (ORR), 4% (complete response (CR) 0%,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u20090; partial response (PR) 4%,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u20091); 6-month progression-free survival (PFS) and overall survival (OS), 32% (95% confidence interval (CI) 18%\u201357%) and 84% (95% CI 71%\u2013100%), respectively. In the remaining histologic subtypes, the confirmed ORR was 9% (CR, 0%,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u20090; PR, 9%,\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u20093); stable disease (SD) &gt;6\u2009months\/PR\/unconfirmed PR\u2009=\u200935%; 6-month PFS and OS, 34% (95% CI 21%\u201355%) and 88% (95% CI 78%\u2013100%), respectively. The most common toxicities were fatigue (39%) and diarrhea (26%); diarrhea (8%) was the most common grade 3\u20134 immune-related adverse event.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In salivary gland tumors, combined ipilimumab plus nivolumab resulted in only a 4% ORR in adenoid cystic carcinoma and 9% in all other histologies combined, though the latter showed clinical benefit (included SD &gt;6\u2009months) in 35% of patients.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial registration:<\/jats:bold>\n                      ClinicalTrials.gov registry: NCT02834013.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261451739","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:07:58Z","timestamp":1784826478000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-7235","authenticated-orcid":false,"given":"Young Kwang","family":"Chae","sequence":"first","affiliation":[{"name":"Medical Oncology, Translational Medicine, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 645 N. Michigan Ave, Ste. 1006, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Sun","sequence":"additional","affiliation":[{"name":"Biostatistics Department, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip P.","family":"Patel","sequence":"additional","affiliation":[{"name":"Medical Oncology, UCSD Moores Cancer Center, 3855 Health Sciences Drive #0987, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Giles","sequence":"additional","affiliation":[{"name":"Medical Oncology, Northwestern University, Chicago, IL, USA"},{"name":"Developmental Therapeutics Consortium, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Ohr","sequence":"additional","affiliation":[{"name":"Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis P.","family":"Worden","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Suga","sequence":"additional","affiliation":[{"name":"Oncology, Kaiser Permanente-Vallejo\/NCORP, Vallejo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, University of Texas\/MD Anderson, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra E.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of California at San Diego Moores Cancer Center, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wallace","sequence":"additional","affiliation":[{"name":"Hematology Oncology, University of Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Seok","family":"Kang","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5102-4948","authenticated-orcid":false,"given":"Sarah","family":"Fenton","sequence":"additional","affiliation":[{"name":"Medical Oncology, Northwestern University, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6541-793X","authenticated-orcid":false,"given":"Liam Il-Young","family":"Chung","sequence":"additional","affiliation":[{"name":"Medical Oncology, Northwestern University, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"McLeod","sequence":"additional","affiliation":[{"name":"SWOG Data Operations Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen X.","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Investigational Drug Branch, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Investigational Drug Branch, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Streicher","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Investigational Drug Branch, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oregon Health &amp; Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Othus","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Seattle, WA, USA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Blanke","sequence":"additional","affiliation":[{"name":"SWOG Group Chair\u2019s Office, Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"Medical Oncology, Medical College of Wisconsin, MCW Cancer Center\/Administrative Office, 9200 West Wisconsin Avenue, Suite C5300, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821218116"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3025"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jobcr.2014.05.003"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/014556130608500201"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2015.11.001"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13952"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197301)31:1<117::AID-CNCR2820310116>3.0.CO;2-7"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1985.tb00522.x"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2005.02.005"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2007.08.018"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21400"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.08.008"},{"key":"e_1_3_4_14_2","volume-title":"WHO classification of head and neck tumors","author":"El-Naggar AK","year":"2017","unstructured":"El-Naggar AK, Chan JKC, Rubin Grandis J, et al. WHO classification of head and neck tumors. Lyon, France: International Agency for Research on Cancer, 2017."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2307\/2530286"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3123"},{"key":"e_1_3_4_17_2","unstructured":"EQUATOR Network. SPIRIT2025 statement: defining standard protocol items for clinical trials https:\/\/www.equator-network.org\/reporting-guidelines\/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials\/ (2025 accessed 6 November 2025)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000915)89:6<1195::AID-CNCR2>3.0.CO;2-J"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(99)00084-5"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10400"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-0709(89)90004-5"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-007-0297-x"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2012.05.004"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328344f59c"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.11.018"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2602"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.01.015"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3758"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24266"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2214"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000429"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70724"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02518-x"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2182"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3356"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33591"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002990"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261451739","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261451739","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261451739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:16:35Z","timestamp":1784985395000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261451739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"alternative-id":["10.1177\/17588359261451739"],"URL":"https:\/\/doi.org\/10.1177\/17588359261451739","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17588359261451739"}}